Efficient lipid-mediated gene transfer to articular chondrocytes

H. Madry, Stephen Trippel

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

We examined nonviral, lipid-mediated gene transfer methods as potential tools for efficient transfection of articular chondrocytes. Transfection conditions were determined for primary cultures of normal human articular, osteoarthritic human articular and normal bovine articular chondrocytes using a lacZ reporter gene construct with the commercially available cationic liposomes Cellfectin, DMRIE-C, Lipofect-Amine, Lipofectin, LipoTaxi, TransFast and the lipid-based reagent FuGENE 6. Optimized conditions were then evaluated in an ex vivo model of chondrocyte transplantation. FuGENE 6 transfection produced the maximum levels of transgene expression. Transfection efficiency was cell type specific and affected by DNA concentration, lipid/DNA ratio and the presence of hyaluronidase, a matrix-degrading enzyme. Analysis of X-gal staining demonstrated an efficiency of 41.0% in normal bovine articular chondrocytes, 20.7% in normal human articular chondrocytes and 7.8% in osteoarthritic human chondrocytes. Transfected chondrocytes were found to successfully populate the articular cartilage surface in explant cultures. Transplanted genetically modified chondrocytes adhered to the articular cartilage and continued to produce β-galactosidase for 2 weeks. This evaluation and optimization of lipid-based gene transfer into articular chondrocytes may serve as a useful tool in studies of genes involved in articular cartilage damage and repair and as a potential delivery method for therapeutic genes.

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalGene Therapy
Volume7
Issue number4
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Chondrocytes
Joints
Lipids
Genes
Transfection
Articular Cartilage
Galactosidases
Lac Operon
Hyaluronoglucosaminidase
DNA
Transgenes
Reporter Genes
Liposomes
Amines
Transplantation
Staining and Labeling
Enzymes

Keywords

  • Articular chondrocytes
  • Cationic liposomes
  • Cell transplantation
  • Gene therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Madry, H., & Trippel, S. (2000). Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Therapy, 7(4), 286-291.

Efficient lipid-mediated gene transfer to articular chondrocytes. / Madry, H.; Trippel, Stephen.

In: Gene Therapy, Vol. 7, No. 4, 02.2000, p. 286-291.

Research output: Contribution to journalArticle

Madry, H & Trippel, S 2000, 'Efficient lipid-mediated gene transfer to articular chondrocytes', Gene Therapy, vol. 7, no. 4, pp. 286-291.
Madry, H. ; Trippel, Stephen. / Efficient lipid-mediated gene transfer to articular chondrocytes. In: Gene Therapy. 2000 ; Vol. 7, No. 4. pp. 286-291.
@article{e3f0074d9fc84c0f92350503da084cb1,
title = "Efficient lipid-mediated gene transfer to articular chondrocytes",
abstract = "We examined nonviral, lipid-mediated gene transfer methods as potential tools for efficient transfection of articular chondrocytes. Transfection conditions were determined for primary cultures of normal human articular, osteoarthritic human articular and normal bovine articular chondrocytes using a lacZ reporter gene construct with the commercially available cationic liposomes Cellfectin, DMRIE-C, Lipofect-Amine, Lipofectin, LipoTaxi, TransFast and the lipid-based reagent FuGENE 6. Optimized conditions were then evaluated in an ex vivo model of chondrocyte transplantation. FuGENE 6 transfection produced the maximum levels of transgene expression. Transfection efficiency was cell type specific and affected by DNA concentration, lipid/DNA ratio and the presence of hyaluronidase, a matrix-degrading enzyme. Analysis of X-gal staining demonstrated an efficiency of 41.0{\%} in normal bovine articular chondrocytes, 20.7{\%} in normal human articular chondrocytes and 7.8{\%} in osteoarthritic human chondrocytes. Transfected chondrocytes were found to successfully populate the articular cartilage surface in explant cultures. Transplanted genetically modified chondrocytes adhered to the articular cartilage and continued to produce β-galactosidase for 2 weeks. This evaluation and optimization of lipid-based gene transfer into articular chondrocytes may serve as a useful tool in studies of genes involved in articular cartilage damage and repair and as a potential delivery method for therapeutic genes.",
keywords = "Articular chondrocytes, Cationic liposomes, Cell transplantation, Gene therapy",
author = "H. Madry and Stephen Trippel",
year = "2000",
month = "2",
language = "English (US)",
volume = "7",
pages = "286--291",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Efficient lipid-mediated gene transfer to articular chondrocytes

AU - Madry, H.

AU - Trippel, Stephen

PY - 2000/2

Y1 - 2000/2

N2 - We examined nonviral, lipid-mediated gene transfer methods as potential tools for efficient transfection of articular chondrocytes. Transfection conditions were determined for primary cultures of normal human articular, osteoarthritic human articular and normal bovine articular chondrocytes using a lacZ reporter gene construct with the commercially available cationic liposomes Cellfectin, DMRIE-C, Lipofect-Amine, Lipofectin, LipoTaxi, TransFast and the lipid-based reagent FuGENE 6. Optimized conditions were then evaluated in an ex vivo model of chondrocyte transplantation. FuGENE 6 transfection produced the maximum levels of transgene expression. Transfection efficiency was cell type specific and affected by DNA concentration, lipid/DNA ratio and the presence of hyaluronidase, a matrix-degrading enzyme. Analysis of X-gal staining demonstrated an efficiency of 41.0% in normal bovine articular chondrocytes, 20.7% in normal human articular chondrocytes and 7.8% in osteoarthritic human chondrocytes. Transfected chondrocytes were found to successfully populate the articular cartilage surface in explant cultures. Transplanted genetically modified chondrocytes adhered to the articular cartilage and continued to produce β-galactosidase for 2 weeks. This evaluation and optimization of lipid-based gene transfer into articular chondrocytes may serve as a useful tool in studies of genes involved in articular cartilage damage and repair and as a potential delivery method for therapeutic genes.

AB - We examined nonviral, lipid-mediated gene transfer methods as potential tools for efficient transfection of articular chondrocytes. Transfection conditions were determined for primary cultures of normal human articular, osteoarthritic human articular and normal bovine articular chondrocytes using a lacZ reporter gene construct with the commercially available cationic liposomes Cellfectin, DMRIE-C, Lipofect-Amine, Lipofectin, LipoTaxi, TransFast and the lipid-based reagent FuGENE 6. Optimized conditions were then evaluated in an ex vivo model of chondrocyte transplantation. FuGENE 6 transfection produced the maximum levels of transgene expression. Transfection efficiency was cell type specific and affected by DNA concentration, lipid/DNA ratio and the presence of hyaluronidase, a matrix-degrading enzyme. Analysis of X-gal staining demonstrated an efficiency of 41.0% in normal bovine articular chondrocytes, 20.7% in normal human articular chondrocytes and 7.8% in osteoarthritic human chondrocytes. Transfected chondrocytes were found to successfully populate the articular cartilage surface in explant cultures. Transplanted genetically modified chondrocytes adhered to the articular cartilage and continued to produce β-galactosidase for 2 weeks. This evaluation and optimization of lipid-based gene transfer into articular chondrocytes may serve as a useful tool in studies of genes involved in articular cartilage damage and repair and as a potential delivery method for therapeutic genes.

KW - Articular chondrocytes

KW - Cationic liposomes

KW - Cell transplantation

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0033994254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033994254&partnerID=8YFLogxK

M3 - Article

C2 - 10694808

AN - SCOPUS:0033994254

VL - 7

SP - 286

EP - 291

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 4

ER -